Salix Pharmaceuticals News

Salix Pharmaceuticals, Ltd. today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis patients who switched from another 5-ASA product Additional ...

BellwetherReport.com Analyst Opinions on FLEX, OSIP, DNDN and SLXP Comtex TORONTO, Oct 06, 2008 ----BellwetherReport.com is the leading online financial newsletter for investors seeking top independent and ...

Salix Pharmaceuticals, Ltd. today announced the successful completion and outcome of its pivotal Phase 3 trial to evaluate the efficacy, safety and tolerability of rifaximin in preventing hepatic ...

Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome Results Presented at American College of Gastroenterology Annual Meeting Demonstrate Quality ...

The National Coalition for Quality Colorectal Cancer Screening and Care announced that Salix Pharmaceuticals, Ltd.

' Imagine if sales of your company's marquee product effectively disappeared overnight.

Zacks Equity Research highlights DeVry, Inc. as the Bull of the Day and Salix Pharmaceuticals as the Bear of the Day.

Salix Pharmaceuticals, a Morrisville company specializing in gastrointestinal medicines, has filed a lawsuit to prevent a competitor from bringing to market a cheaper, generic version of its bowel cleanser ...

Slayton Search Partners has recruited John Thornton as Executive Vice President, Sales and Marketing and Leslie Bostic as Senior Vice President, Human Resources to - WASHINGTON-- --The Hispanic Leadership Fund ...

Salix Pharmaceuticals plans to boost its business by selling $50 million in convertible notes to institutional buyers, the Raleigh drug maker said Monday.

Salix Pharmaceuticals Ltd. August 04, 2008 5:00 pm ET Executives Michael Freeman - Associate VP of IR and Corporate Communications Carolyn Logan - President and CEO Adam Derbyshire - SVP and CFO Analysts Scott ...

RALEIGH, N.C., July 30, 2008-- --Salix Pharmaceuticals, Ltd. today announced that the Company will present at two health care investment conferences during August 2008.

CORVALLIS, OR, July 28 / MARKET WIRE/ -- AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced that J. David Boyle II will join the Company as Senior Vice President and Chief Financial Officer.

CORVALLIS, OR, July 28 / MARKET WIRE/ -- AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced that J. David Boyle II will join the Company as Senior Vice President and Chief Financial Officer.

CORVALLIS, OR, July 28 / MARKET WIRE/ -- AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced that J. David Boyle II will join the Company as Senior Vice President and Chief Financial Officer.

CORVALLIS, OR, July 28 / MARKET WIRE/ -- AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced that J. David Boyle II will join the Company as Senior Vice President and Chief Financial Officer.

CORVALLIS, OR, July 28 / MARKET WIRE/ -- AVI BioPharma, Inc. , a developer of RNA-based drugs, today announced that J. David Boyle II will join the Company as Senior Vice President and Chief Financial Officer.

Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List Stocks to Sell Now.

Salix Pharmaceuticals, Ltd. today announced that the Company has initiated patient enrollment in TARGET 1 and TARGET 2, its Phase 3, randomized, double-blind, placebo-controlled, multicenter studies to assess ...

Salix Pharmaceuticals, Ltd. today announced that the Company will present at the UBS Global Specialty and Generic Pharmaceuticals Conference in - 05/22/2008 - 07:00 AM ATLANTA-- --Cumulus Media Inc.